2015 Grant Recipient Gregory Beatty, MD, PhD

Home Research Research Grants Program Grants Awarded Grants Awarded by Year 2015 Pancreatic Cancer Action Network Research Grants 2015 Grant Recipient Gregory Beatty, MD, PhD

GRANTEE: Gregory Beatty, MD, PhD
University of Pennsylvania
Research Project: Immune escape mechanisms in metastatic pancreatic cancer

Award: 2015 Pancreatic Cancer Action Network – AACR Career Development Award (Grant funded by an anonymous foundation)
Award Period: July 1, 2015 – June 30, 2017
Amount: $200,000

Biographical Highlights
Dr. Beatty is an assistant professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and in the division of hematology/oncology within the Abramson Cancer Center at the Hospital of the University of Pennsylvania. Dr. Beatty graduated from Bucknell University with a BS in chemical engineering and then earned his PhD in immunology followed by an MD from the University of Pennsylvania Perelman School of Medicine. He went on to complete a residency in internal medicine and a fellowship in medical oncology at the Hospital of the University of Pennsylvania. Dr. Beatty’s research interest is in understanding the role of macrophages in regulating innate and adaptive immunosurveillance in cancer. He has developed a research platform within his laboratory that uses genetically engineered mouse models of cancer to study leukocyte biology within the tumor microenvironment and to screen novel immunotherapeutic strategies for the treatment of pancreatic cancer. In addition, he is currently leading several early phase clinical studies investigating immunotherapeutic approaches for pancreatic cancer.

Project Overview
One of the survival mechanisms of cancer cells is their ability to avoid recognition and attack by the patient’s immune system. Cancer immunotherapeutic approaches strive to prevent this evasion and harness the immune system to fight the tumor. A hallmark of pancreatic cancer is its tendency to metastasize, or spread, to other organs, most frequently the liver. Under normal conditions, pancreas cells within the liver would be deemed “foreign” and destroyed by the immune system. Preliminary data suggest that under metastatic conditions, this outcome is prevented by the immune cells within the liver tissue environment welcoming the pancreatic cancer cells, and the cancer cells themselves signaling to the immune system to allow their presence. Dr. Beatty’s project entails studying the role the immune system plays in allowing and facilitating pancreatic cancer metastasis and devising immunotherapeutic strategies to block metastatic spread.

For this project, Dr. Beatty will utilize a genetically engineered mouse model of pancreatic cancer whereby the disease progression and spread mimic human disease. He proposes to systematically eliminate specific types of immune cells in livers of the mice in order to determine which cells enable the metastatic spread of the pancreatic cancer cells. In addition, Dr. Beatty and his research team will examine ways to alter the liver immune cells to train them to attack, rather than welcome, the cancer cells, as well as methods to alter the cancer cells so that they are more easily recognizable by the immune cells as foreign. Overall, Dr. Beatty’s project intends to provide insight into factors that regulate pancreatic cancer metastasis and to inform the development of novel immunotherapeutic approaches for inhibiting and treating metastatic disease.

Wage Hope With Us

Join us to double pancreatic cancer survival by 2020.





shop purple logo

Gear, apparel, accessories and more to show off your purple pride.


Shop Now 

©2018 Pancreatic Cancer Action Network. All rights reserved. Terms of Use | Privacy Policy


Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.


The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.